

SUPPLEMENTAL DATA

Supplementary Table 1. Antibodies used for immunohistochemistry.

| Antibody name | Company and catalog number |
|------------------------------------|----------------------------|
| anti-NF- κ B | CST, 8242S |
| anti-Nrf2 | Abcam, ab137550 |
| anti-8-OHdG | Bioss, bs-1278R |
| anti- β -tubulin isotype III | Sigma Aldrich, T8578 |

Supplementary Table 2. Antibodies used for Western blotting.

| Antibody name | Company and catalog number |
|------------------------------|--|
| anti-p-AMPK | Cell Signaling Technology (CST), 4185S |
| anti-AMPK | CST, 2532S |
| anti-SIRT1 | Abcam, ab110304 |
| anti-PGC-1 α | Abcam, ab54481 |
| anti-p-ACC | CST, 11818S |
| anti-COX IV | Proteintech, 11242-1-AP |
| anti-NDUFS3 | Proteintech, 15066-1-AP |
| anti-TNF- α | CST, 11948S |
| anti- iNOS | CST, 13120S |
| anti-ERK | CST, 4695S |
| anti- β -actin | Abcam, ab8226 |
| anti-p-I κ B α | CST, 9246S |
| anti-I κ B α | CST, 4812S |
| anti-p-Akt | CST, 13038T |

| | |
|--------------|------------|
| anti-AKT | CST, 9272S |
| anti-p-mTOR | CST, 5536S |
| anti- mTOR | CST, 2972S |
| anti-p-NF-κB | CST, 3033S |
| anti- NF-κB | CST, 8242 |

Supplementary Table 3. The pharmacokinetic parameters of DW15139 by IV delivery.

| IV delivery (10 mg/kg) | | Parameter | DW15139 | DW14006 |
|---------------------------|----------------------|-----------|---------|----------|
| Plasma | C _{max} | ng/mL | / | 17911.12 |
| | t _{max} | h | / | 0.05 |
| | t _{1/2} | h | 0.36 | 2.01 |
| | AUC _{0-12h} | h*ng/mL | 1269.90 | 4203.04 |
| DRG | C _{max} | ng/g | 831.30 | 525.38 |
| | t _{max} | h | 0.05 | 0.18 |
| | t _{1/2} | h | / | 2.74 |
| | AUC _{0-12h} | h*ng/g | 295.80 | 641.06 |

/ indicates parameter cannot be calculated.

Supplementary Table 4. The pharmacokinetic parameters of DW15139 by PO delivery.

| PO delivery (30 mg/kg) | | Parameter | DW15139 | DW14006 |
|---------------------------|----------------------|-----------|---------|---------|
| Plasma | AUC _{0-12h} | h*ng/mL | 1.63 | 49.41 |
| DRG | AUC _{0-12h} | h*ng/g | 295.80 | 588.04 |

/ indicates parameter cannot be calculated. As indicated in **Supplementary Table 3-4**, after DW15139 (IV or PO) administration, we monitored DW15139 and its hydrolysate

DW14006 in plasma or target tissue (DRG). Plasma and snap-frozen DRG were collected at 8 time points (n = 6/each point, half male and half female C57BL/6 mice) for analysis of DW15139 and DW14006 levels by LC/MS/MS assay. Data are the mean values.

Supplementary Table 5. LD₅₀ calculation of DW14006 against C57BL/6 mice (*i.p*)

| Groups | Number(n) | Dose(mg/kg) | Log of dose | death rate |
|--------|-----------|-------------|-------------|------------|
| 1 | 8 | 640 | 2.8062 | 1 |
| 2 | 8 | 512 | 2.7093 | 1 |
| 3 | 8 | 409.60 | 2.6124 | 1 |
| 4 | 8 | 327.68 | 2.5154 | 1 |
| 5 | 8 | 262.14 | 2.4185 | 0.5 |
| 6 | 8 | 209.72 | 2.3216 | 0 |

$LD_{50} = \lg^{-1} \{X_m - i(\sum p - 0.5)\}$ (X_m : the highest dose converted to logarithm; i : Difference of dose logarithm between adjacent groups; $\sum p$: sum of death rate)

$LD_{50} = \lg^{-1} \{2.8062 - 0.0969(4.5 - 0.5)\} = 262.1682 \text{ mg/kg.}$